January 05th, 2015

Corline is granted Regenerative Medicine patent in Canada

Swedish company Corline Systems AB, maker and distributor of a proprietary and unique heparin coating technology for use in regenerative medicine, has been granted approval of patent application No. 2,612,621 by the Canadian Intellectual Property Office. “The patent secures Corline’s core IP in a very important and innovative market. It was in Edmonton, Canada that the transplantation of cells to diabetes type 1 patients was first developed to a successful therapy, and many companies have been started to build upon this early success in regenerative medicine. The newly granted patent will form a cornerstone in our company’s strategy for this fast evolving industry”, comments CEO Henrik Nittmar.

The new patent – titled ‘Heparin Coating of Biological Tissue’ – covers methods for application and use of the company’s proprietary heparin coating technology for coating all types of biological tissue, such as living cells for transplantation, tissue segments and decellularized tissue matrices. The patent has previously been granted in US, Europe, Australia and Japan. Corline is developing its technology for use in a multitude of clinical applications in the Regenerative Medicine space, both in partnership with industrial companies from many corners of the world, and together with international research groups in Europe, the US and Australia. A common denominator is that all projects use the same core technology, the one that now has gained improved protection by the newly granted patent application. One example of Corline’s internally developed project is using its unique heparin coating technology, CHS, to protect cells used for different types of cell therapies. In this setting CHS can attenuate blood mediated inflammatory reactions and save valuable implanted cells from destruction when transplanted to patients, and improve therapeutic efficacy. The Swedish Medical Products Agency has given its approval to start clinical trials for this promising technology for patients with severe diabetes type-1, and the project recently received a grant to by the Swedish government to start that trial. “On the basis of previously communicated EU and Swedish government grants, we are moving into clinical trials with our core technology in Europe for cell therapy. In parallel we are marketing our technology to several partners in the US and Canada”, concludes CEO Henrik Nittmar.

Back to overview